Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-3β therapies for bipolar disorders

Journal of the American Chemical Society

Volumn 129, Issue 26, 2007, Pages 8328-8332

  Kozikowski, Alan P ^a   Gaisina, Irina N ^a   Yuan, Hongbin ^a   Petukhov, Pavel A ^a   Blond, Sylvie Y ^a   Fedolak, Allison ^b   Caldarone, Barbara ^b   McGonigle, Paul ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b PSYCHOGENICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITORS; NEUROPROTECTION; RODENTS; WEIGHT GAIN;

ENZYMES; LIGANDS; PATHOLOGY; PHYSIOLOGICAL MODELS; RATS; STABILIZERS (AGENTS);

LITHIUM;

3 (BENZOFURAN 3 YL) 4 (INDOL 3 YL)MALEIMIDE; AMPHETAMINE; CHLORDIAZEPOXIDE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; LIGAND; LITHIUM; MOOD STABILIZER; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIPOLAR DISORDER; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MALE; MANIA; MOLECULAR MODEL; MOOD DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; RODENT; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN;

AMPHETAMINE; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CHLORDIAZEPOXIDE; DRUG DESIGN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM; MICE; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34447117684     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja068969w     Document Type: Article

References (36)

1. Woodgett, J. R. EMBO J. 1990, 9, 2431.
2. Welsh, G. I.; Proud, C. G. Biochem. J. 1993, 294, 625.
3. Cohen, P.; Frame, S. Nat. Rev. Mol. Cell. Biol 2001, 2, 769.
4. Dominguez, I.; Green, J. B. Dev. Biol. 2001, 235, 303.
5. Kim, L.; Kimmel, A. R. Curr. Opin. Genet. Dev. 2000, 10, 508.
6. Jope, R. S.; Bijur, G. N. Mol. Psychiatry 2002, 7, 35.
7. Gould, T. D.; Chen, G.; Manji, H. K. Neuropsychopharmacology 2004, 29, 32.
8. Madsen, T. M.; Newton, S. S.; Eaton, M. E.; Russell, D. S.; Duman, R. S. Biol. Psychiatry 2003, 54, 1006.
9. Hall, A. C.; Brennan, A.; Goold, R. G.; Cleverley, K.; Lucas, F. R.; Gordon-Weeks, P. R.; Salinas, P. C. Mol. Cell Neurosci. 2002, 20, 257.
10. Mai, J.; Sameni, M.; Mikkelsen, T.; Sloane, B. F. Biol. Chem. 2002, 383, 1407.
11. Gould, T. D.; Manji, H. K. Neuroscientist 2002, 8, 497.
12. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormo, M.; Nilsson, Y.; Radesater, A. C.; Jerning, E.; Markgren, P. O.; Borgegard, T.; Nylof, M.; Gimenez-Cassina, A.; Hernandez, F.; Lucas, J. J.; Diaz-Nido, J.; Avila, J. J. Biol. Chem. 2003, 278, 45937.
13. Klemfuss, H. Pharmacol. Ther. 1992, 56, 53.
14. Lenox, R. H.; Gould, T. D.; Manji, H. K. Am. J. Med. Genet. 2002, 114, 391.
15. O'Brien, W. T.; Harper, A. D.; Jove, F.; Woodgett, J. R.; Maretto, S.; Piccolo, S.; Klein, P. S. J. Neurosci. 2004, 24, 6791.
16. Kozikowski, A. P.; Gaisina, I. N.; Petukhov, P. A.; Sridhar, J.; King, L. T.; Blond, S. Y.; Duka, T.; Rusnak, M.; Sidhu, A. ChemMedChem 2006, 1, 256.
17. Davis, P. D.; Hill, C. H.; Lawton, G.; Nixon, J. S.; Wilkinson, S. E.; Hurst, S. A.; Keech, E.; Turner, S. E. J. Med. Chem. 1992, 35, 177.
18. Shen, M.; Beguin, C.; Golbraikh, A.; Stables, J. P.; Kohn, H.; Tropsha, A. J. Med. Chem. 2004, 47, 2356.
19. Zhang, K. Y.; Card, G. L.; Suzuki, Y.; Artis, D. R.; Fong, D.; Gillette, S.; Hsieh, D.; Neiman, J.; West, B. L.; Zhang, C.; Milburn, M. V.; Kim, S. H.; Schlessinger, J.; Bollag, G. Mol. Cell 2004, 15, 279.
20. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. J. Chem. Inf. Comput. Sci. 2001, 41, 1308.
21. Martin, Y. C. J. Med. Chem. 2005, 48, 3164.
22. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Delivery Rev. 1997, 23, 3.
23. Lipinski, C. A. J. Pharmacol. Toxicol. Methods 2000, 44, 235.
24. Cruciani, C.; Crivori, P.; Carrupt, P. A.; Testa, B. J. Mol. Struct. 2000, 503, 17.
25. SYBYL, version 7.0; Tripos Inc.: St. Louis, 2004.
26. Faul, M. M.; Winneroski, L. L.; Krumrich, C. A. Tetrahedron Lett. 1999, 40, 1109.
27. Deshpande, A. R.; Paradkar, M. V. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1992, 31, 526.
28. Poitou, P.; Boulu, R.; Bohuon, C. Experientia 1975, 31, 99.
29. Aylmer, C. G.; Steinberg, H.; Webster, R. A. Psychopharmacology 1987, 91, 198.
30. Vale, A. L.; Ratcliffe, F. Psychopharmacology 1987, 91, 352.
31. Hanania, T.; Dillon, G. M.; Malekiani, S. A.; Manzano, M. L.; Leahy, E. Soc. Neurosci. Abstr. 2005, 108.9.
32. Arban, R.; Maraia, G.; Brackenborough, K.; Winyard, L.; Wilson, A.; Gerrard, P.; Large, C. Behav. Brain Res. 2005, 158, 123.
33. Woodgett, J. R. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2003, 3, 281.
34. Gould, T. D.; Gray, N. A.; Manji, H. K. Pharmacol. Res. 2003, 48, 49.
35. Kratz, J. E.; Stearns, D.; Huso, D. L.; Slunt, H. H.; Price, D. L.; Borchelt, D. R.; Eberhart, C. G. BMC Cancer 2002, 2, 33.
36. Johnson, C. D.; Puntis, M.; Davidson, N.; Todd, S.; Bryce, R. Br. J. Surg. 2001, 88, 662.